Document Classification

Section Type: RESULTS

Text: Compared with the FU/LV control arm, treatment with bevacizumab (at both dose levels) plus FU/LV resulted in higher response rates (control arm, 17 %, 95 % confidence interval [CI], 7 % to 34 % ; low-dose arm, 40 %, 95 % CI, 24 % to 58 % ; high-dose arm, 24 %, 95 % CI, 12 % to 43 %), longer median time to disease progression (control arm, 5. 2 months, 95 % CI, 3. 5 to 5. 6 months ; low-dose arm, 9. 0 months, 95 % CI, 5. 8 to 10. 9 months ; high-dose arm, 7. 2 months, 95 % CI, 3. 8 to 9. 2 months), and longer median survival (control arm, 13. 8 months ; 95 % CI, 9. 1 to 23. 0 months ; low-dose arm, 21. 5 months, 95 % CI, 17. 3 to undetermined ; high-dose arm, 16. 1 months ; 95 % CI, 11. 0 to 20. 7 months).